Intelligent Bio Solutions (INBS) Common Equity (2019 - 2024)
Intelligent Bio Solutions has reported Common Equity over the past 6 years, most recently at $11.0 million for Q1 2024.
- Quarterly results put Common Equity at $11.0 million for Q1 2024, up 85.56% from a year ago — trailing twelve months through Mar 2024 was $11.0 million (up 85.56% YoY), and the annual figure for FY2023 was $3.7 million, down 43.67%.
- Common Equity for Q1 2024 was $11.0 million at Intelligent Bio Solutions, up from $3.2 million in the prior quarter.
- Over the last five years, Common Equity for INBS hit a ceiling of $18.8 million in Q4 2020 and a floor of -$5.9 million in Q1 2020.
- Median Common Equity over the past 5 years was $6.5 million (2022), compared with a mean of $6.8 million.
- Biggest five-year swings in Common Equity: surged 543.02% in 2021 and later tumbled 76.2% in 2023.
- Intelligent Bio Solutions' Common Equity stood at $18.8 million in 2020, then tumbled by 46.52% to $10.0 million in 2021, then rose by 2.17% to $10.3 million in 2022, then crashed by 69.27% to $3.2 million in 2023, then soared by 248.67% to $11.0 million in 2024.
- The last three reported values for Common Equity were $11.0 million (Q1 2024), $3.2 million (Q4 2023), and $1.2 million (Q3 2023) per Business Quant data.